Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3693133 | 0.98 | CYP11B2 (0.31) | — | |
| SCHEMBL218979 | 0.98 | CYP11B2 (0.31) | — | |
| SCHEMBL2971884 | 0.95 | — | — | |
| SCHEMBL217251 | 0.90 | — | — | |
| SCHEMBL4537045 | 0.83 | — | — | |
| SCHEMBL2323262 | 0.76 | — | — | |
| SCHEMBL481596 | 0.74 | — | — | |
| SCHEMBL8122799 | 0.71 | — | — | |
| SCHEMBL4542108 | 0.64 | DAO (0.31) | — | |
| SCHEMBL217366 | 0.61 | HTR3A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 574 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104159929-A | Supported composite metallocene catalyst, method for preparing the same, and method for preparing polyolefin using the same | SK INNOVATION CO LTD | 2014-11-19 | — | — | CN | claimed |
| US-7276567-B2 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-10-02 | — | — | US | claimed |
| US-20030207757-A1 | Catalyst composition comprising metallocene compound having bulky cycloalkyl-substituted cyclopentadienyl ligand, and process for olefin polymerization using the same | DAELIM INDUSTRIES CO., LTD. (KR) | 2003-11-06 | — | — | US | claimed |
| CN-112689634-B | SMAD3 inhibitors | 莫扎制药有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118355029-A | Methods of treating diffuse large B-cell lymphomas using anti-CD 79B immunoconjugates | 基因泰克公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240226342-A1 | REACTIVE OXYGEN SPECIES IMAGING AGENTS | WASHINGTON UNIVERSITY (US) | 2024-07-11 | — | — | US | disclosed |
| US-12016842-B2 | Methods of using anti-CD79b immunoconjugates | GENENTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| EP-4380978-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | Genentech, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-11998584-B2 | Conjugate of a tubulysin analog with branched linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-06-04 | — | — | US | disclosed |
| US-20240179825-A1 | SYSTEMS AND METHODS FOR NONEQUILIBRIUM PLASMAS | WASHINGTON UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| US-6258744-B1 | OLEFIN POLYMERIZATION CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-10 | — | — | US | disclosed |
| EP-1066296-A1 | NOVEL DENDRIMER COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS CATALYSTS | Bayer Aktiengesellschaft (DE) | 2001-01-10 | — | — | EP | disclosed |
| EP-1063243-A2 | Olefin polymerization process and catalyst system therefor | BAYER AG (DE) | 2000-12-27 | — | — | EP | disclosed |
| CN-1278265-A | Process for preparing fulvene metal complexes | BAYER AG (DE) | 2000-12-27 | — | — | CN | disclosed |
| EP-1028968-A1 | METHOD FOR PRODUCING FULVENE METAL COMPLEXES | BAYER AG (DE) | 2000-08-23 | — | — | EP | disclosed |
| CN-1246486-A | Catalyst system based on fulvene metal compound | BAYER AG (DE) | 2000-03-08 | — | — | CN | disclosed |
| EP-0982319-A2 | Catalyst system based on fulvene-cyclopentadienyl-metal complexes | Bayer Aktiengesellschaft (DE) | 2000-03-01 | — | — | EP | disclosed |
| WO-1999048898-A1 | NOVEL DENDRIMER COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS CATALYSTS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999024445-A1 | METHOD FOR PRODUCING FULVENE METAL COMPLEXES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226342-A1 | REACTIVE OXYGEN SPECIES IMAGING AGENTS | ROS1, NOX4, CYBB | MAOA 542/4885MAOB 319/4885 |
| US-12016842-B2 | Methods of using anti-CD79b immunoconjugates | CD79B, CD99, BCL6 | MAOA 4021/4885MAOB 1050/4885 |
| US-11998584-B2 | Conjugate of a tubulysin analog with branched linkers | TEKT1, TEK, CD2BP2 | MAOA 4139/4885MAOB 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.